Research into next-generation immunotherapy biologics is being explored as a potential treatment for glioblastoma. The development of these therapies is seen as an opportunity to address the challenges of treating this type of brain cancer. Several companies and institutions, including some involved in recent acquisitions and partnerships, are working on emerging strategies for precision immunotherapy.